Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

NCT00689936 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1623

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Lenalidomide and low-dose dexamethasone
DRUG: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
DRUG: Melphalan, Prednisone and Thalidomide

Sponsor

Celgene